Heron Therapeutics Inc. (HRTX) announced Monday morning that its Phase 3 studies of HTX-011 in subjects undergoing bunionectomy and hernia repair achieved all primary and key secondary endpoints.
from RTT - Before the Bell http://ift.tt/2FOGh4f
via IFTTT
No comments:
Post a Comment